vs

Side-by-side financial comparison of Strategy Inc (MSTR) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.

Protagonist Therapeutics, Inc is the larger business by last-quarter revenue ($170.6M vs $123.0M, roughly 1.4× Strategy Inc). On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 1.9%).

Strategy Inc., formerly known as MicroStrategy, is an American company that provides business intelligence (BI) and mobile software. Founded in 1989 by Michael J. Saylor, Sanju Bansal, and Thomas Spahr, the firm develops software to analyze internal and external data in order to make business decisions and to develop mobile apps. It is a public company headquartered in Tysons Corner, Virginia, in the Washington metropolitan area. Its primary business analytics competitors include SAP SE Busin...

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.

MSTR vs PTGX — Head-to-Head

Bigger by revenue
PTGX
PTGX
1.4× larger
PTGX
$170.6M
$123.0M
MSTR
Growing faster (revenue YoY)
PTGX
PTGX
+182.5% gap
PTGX
184.4%
1.9%
MSTR

Income Statement — Q2 FY2026 vs Q4 FY2024

Metric
MSTR
MSTR
PTGX
PTGX
Revenue
$123.0M
$170.6M
Net Profit
$131.7M
Gross Margin
66.1%
Operating Margin
74.3%
Net Margin
77.2%
Revenue YoY
1.9%
184.4%
Net Profit YoY
381.7%
EPS (diluted)
$2.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MSTR
MSTR
PTGX
PTGX
Q4 25
$123.0M
Q3 25
$128.7M
Q2 25
$114.5M
Q1 25
$111.1M
Q4 24
$120.7M
$170.6M
Q3 24
$116.1M
Q2 24
$111.4M
Q1 24
$115.2M
$255.0M
Net Profit
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
$2.8B
Q2 25
$10.0B
Q1 25
$-4.2B
Q4 24
$-670.8M
$131.7M
Q3 24
$-340.2M
Q2 24
$-102.6M
Q1 24
$-53.1M
$207.3M
Gross Margin
MSTR
MSTR
PTGX
PTGX
Q4 25
66.1%
Q3 25
70.5%
Q2 25
68.8%
Q1 25
69.4%
Q4 24
71.7%
Q3 24
70.4%
Q2 24
72.2%
Q1 24
74.0%
Operating Margin
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
Q2 25
Q1 25
-5331.4%
Q4 24
-842.1%
74.3%
Q3 24
-372.7%
Q2 24
-179.7%
Q1 24
-176.8%
80.9%
Net Margin
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
2164.1%
Q2 25
8752.7%
Q1 25
-3797.2%
Q4 24
-555.8%
77.2%
Q3 24
-293.1%
Q2 24
-92.0%
Q1 24
-46.1%
81.3%
EPS (diluted)
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
$8.42
Q2 25
$32.60
Q1 25
$-16.49
Q4 24
$4.49
$2.01
Q3 24
$-1.72
Q2 24
$-0.57
Q1 24
$-0.31
$3.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MSTR
MSTR
PTGX
PTGX
Cash + ST InvestmentsLiquidity on hand
$2.3B
$418.9M
Total DebtLower is stronger
$8.2B
Stockholders' EquityBook value
$44.1B
$675.3M
Total Assets
$61.6B
$744.7M
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MSTR
MSTR
PTGX
PTGX
Q4 25
$2.3B
Q3 25
$54.3M
Q2 25
$50.1M
Q1 25
$60.3M
Q4 24
$38.1M
$418.9M
Q3 24
$46.3M
Q2 24
$66.9M
Q1 24
$81.3M
$322.6M
Total Debt
MSTR
MSTR
PTGX
PTGX
Q4 25
$8.2B
Q3 25
$8.2B
Q2 25
$8.2B
Q1 25
$8.1B
Q4 24
$7.2B
Q3 24
$4.2B
Q2 24
$3.8B
Q1 24
$3.6B
Stockholders' Equity
MSTR
MSTR
PTGX
PTGX
Q4 25
$44.1B
Q3 25
$52.3B
Q2 25
$47.5B
Q1 25
$32.2B
Q4 24
$18.2B
$675.3M
Q3 24
$3.8B
Q2 24
$2.8B
Q1 24
$2.4B
$560.4M
Total Assets
MSTR
MSTR
PTGX
PTGX
Q4 25
$61.6B
Q3 25
$73.6B
Q2 25
$64.8B
Q1 25
$43.9B
Q4 24
$25.8B
$744.7M
Q3 24
$8.3B
Q2 24
$7.1B
Q1 24
$6.4B
$629.3M
Debt / Equity
MSTR
MSTR
PTGX
PTGX
Q4 25
0.19×
Q3 25
0.16×
Q2 25
0.17×
Q1 25
0.25×
Q4 24
0.39×
Q3 24
1.12×
Q2 24
1.36×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MSTR
MSTR
PTGX
PTGX
Operating Cash FlowLast quarter
$184.2M
Free Cash FlowOCF − Capex
$182.8M
FCF MarginFCF / Revenue
107.1%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
1.40×
TTM Free Cash FlowTrailing 4 quarters
$101.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
$-8.3M
Q2 25
$-34.9M
Q1 25
$-2.4M
Q4 24
$-17.3M
$184.2M
Q3 24
$-41.0M
Q2 24
$-23.3M
Q1 24
$28.6M
$-27.4M
Free Cash Flow
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
$-11.1M
Q2 25
$-37.0M
Q1 25
$-5.1M
Q4 24
$-17.6M
$182.8M
Q3 24
$-41.4M
Q2 24
$-24.1M
Q1 24
$27.0M
$-27.7M
FCF Margin
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
-8.6%
Q2 25
-32.3%
Q1 25
-4.6%
Q4 24
-14.6%
107.1%
Q3 24
-35.7%
Q2 24
-21.6%
Q1 24
23.5%
-10.9%
Capex Intensity
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
2.2%
Q2 25
1.8%
Q1 25
2.5%
Q4 24
0.2%
0.8%
Q3 24
0.4%
Q2 24
0.6%
Q1 24
1.3%
0.1%
Cash Conversion
MSTR
MSTR
PTGX
PTGX
Q4 25
Q3 25
-0.00×
Q2 25
-0.00×
Q1 25
Q4 24
1.40×
Q3 24
Q2 24
Q1 24
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons